Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Post-Menopausal Osteoporosis

  • A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
    Recruiting


  • BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
    No longer recruiting


  • A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
    No longer recruiting


  • BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
    No longer recruiting


  • A Study of Adherence to Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP).
    No longer recruiting


  • A Study Comparing Monthly Bonviva (Ibandronate) and Weekly Alendronate in Women With Post-Menopausal Osteoporosis.
    No longer recruiting


  • SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
    No longer recruiting


  • A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
    No longer recruiting


  • A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
    No longer recruiting


  • ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
    Completed


  • A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
    Completed


  • MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
    Completed


  • DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
    Completed


  • A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
    Completed


  • A Study of Bonviva (Ibandronate) in Patients With Post-Menopausal Osteoporosis
    Completed


  • A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
    Completed


  • A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
    Completed


  • A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
    Completed


  • A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
    Completed


  • A Study of Boniva (Ibandronate) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
    Completed


  • A Study of Boniva (Ibandronate) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Post-Menopausal Osteoporosis
    Completed


  • PRIOR Study - A Study of Boniva (Ibandronate) in Postmenopausal Women With Osteoporosis or Osteopenia
    Completed


  • A Study of Bonviva (Ibandronic Acid) in Women With Post-Menopausal Osteoporosis
    Completed


  • A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
    Completed


  • BonAdAsia study--A Study of Once Monthly Bonviva (Ibandronate)in Women With Post-Menopausal Osteoporosis
    Completed


  • ATOM study:A Study of Adherence to Bonviva (Ibandronate)Once Monthly in Women With Post-Menopausal Osteoporosis
    Completed


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement